Kristina Torfgård has experience in executive management, drug development, regulatory affairs and licensing with major international pharmaceutical companies, including in the field of neurodegenerative diseases.

During her time at AstraZeneca, she held senior positions in both early and late-stage R&D and was globally responsible for marketed products. At the biopharmaceutical company Albireo/Pharma, she worked as VP Clinical & Regulatory Affairs and VP Global Project Head. Most recently, she was CEO of Alzinova where she built up the company to bring drug candidates for Alzheimer’s disease to the market through partnering. She is a pharmacist and holds a PhD in Medical Science from Linköping University. She is a Board director of GU Ventures, the holding company at the University of Gothenburg.

“I am delighted to have been entrusted by the Board of Directors to lead IRLAB, an impressive company that through its unique research platform, ISP, has created a world-leading project portfolio in the field of Parkinson’s,” says Torfgård.

Gunnar Olsson will continue to be involved in the company in his role as a Board director also after the change of CEO on August 1, 2024.

Photo: Alzinova